The PDGFC CUB Domain Enhances Survival in PDGFC Mutant Mice

Brian J. Hayes¹, Kimberly J. Riehle^{1,2}, Debra G. Gilbertson³, Wendy R. Curtis³, Edward J. Kelly⁴,
Piper M. Treuting⁵ and Jean S. Campbell^{1*}

¹Department of Pathology, University of Washington, Seattle, WA 98195, USA

²Department of Surgery, University of Washington, Seattle, WA 98195, USA

³Zymogenetics Inc, a Bristol-Myers Squibb Company, Seattle, WA 98102, USA

⁴Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA

⁵Department of Comparative Medicine, University of Washington, Seattle, WA 98195, USA

Received: May 01, 2015; Accepted: August 27, 2015; Published: September 14, 2015

*Corresponding author: Jean S. Campbell, Executive Director of Research and Development, Oncosec Medical, 434 N. 34th St, Suite 100; Seattle, WA 98103, USA, Tel: +(206) 221-5422; E-mail: jcampbell@oncosec.com

Abstract

Platelet-derived growth factor (PDGF) signaling pathways are necessary for normal development. Here we report a homozygous *Pdgfr-c* mutant mouse that is viable. In this mouse, alternative splicing gives rise to a truncated transcript containing the entire coding region of the complement components C1r/C1s sea urchin EGF bone morphogenetic protein 1 (CUB) domain of PDGFC but lacking the majority of the Growth Factor Domain (GFD). A mutant protein is translated from the truncated sequence *in vitro*. However, the viability of our homozygous mutant *Pdgfr-c* mice depends on the presence of both *Pdgfra* alleles.

Keywords: PDGFC; Cleavage, Growth factor; Knockout

Introduction

The platelet-derived growth factor (PDGF) signal transduction pathway has important functions in development. Mice lacking PDGF receptor (PDGFR) α or β are embryonic lethal [1,2], and deletion of *Pdgfr-a*, *-b*, or *-c* results in perinatal lethality in homozygous Knockout (KO) animals, though live births are seen in *Pdgfr-a* and *Pdgfr-c* KO mice [3-5]. *In vitro* studies demonstrate that PDGF-AA, -BB, and -CC induce *Pdgfra* dimerization, PDGF-BB, and PDGF-DD induce dimerization of *Pdgrfr β* , and -AB, -BB, and -CC induce $\alpha\beta$ -receptor dimerization [6]. As predicted by *in vitro* binding studies, *Pdgfr-b* KO mice have a phenotype similar to *Pdgfr-b* KO mice, with defects in kidney and hematologic development [2,4]. Mice lacking PDGFA have a defect in lung development [3], and interestingly do not phenocopy deletion of *Pdgfra*, which causes abnormalities in skeletal development and neural crest migration [1,7]. On the other hand, *Pdgfr-c* KO animals, referred to as *Pdgfr^{tm1nag}*, have a defect in palate formation, resulting from abnormal neural crest cell migration and proliferation [5]. Ding, et al. [5], further reported that *Pdgfr-a*, *Pdgfr-c* double KO mice have a phenotype similar to *Pdgfra* KO mice, suggesting that PDGF-C is a major activator of *Pdgfra* signal transduction in the context of development.

PDGF-AA, PDGF-BB, and PDGF-AB are secreted as active dimers [8], while PDGF-CC and PDGF-DD are secreted as inactive homodimers requiring extracellular cleavage of an N-terminal complement components C1r/C1s sea urchin EGF bone morphogenetic protein 1 (CUB) domain to allow receptor binding (Figure 1a) [9-12]. All PDGFs share a common growth factor domain (GFD), which is 110 amino acids long and contains 8 conserved cysteines that facilitate intra- and intermolecular disulfide bonds [13]. PDGF signal transduction is mediated through the GFD, and mutations of these cysteines and loss of their disulfide bonds cause a lack of PDGFR signal transduction [14,15]. Furthermore, mutation of sequences in loops I, II, or III of the GFD, the domain that physically interacts with PDGFRs, decreases the GFD's ability to bind PDGFRs [16-18]. Effective signal transduction by *Pdgfr-c* thus should require the conserved cysteines and loops I-III of the GFD, as well as cleavage of the CUB domain. We hypothesized that deletion of the majority of the GFD would thus eliminate receptor binding and downstream signal transduction. Contrary to our hypothesis, we describe a homozygous *Pdgfr-c* mutant mouse wherein most of the GFD is indeed deleted, but the expression of the CUB domain in these mice is sufficient for viability. Viability, however, depends on genetic background, as has been described for other *Pdgfra* mutations [19,20].

Methods

Mouse Models

The *Pdgfr-c* locus was isolated from a 129S5/SvEvBrd genomic BAC library. The targeting construct replaced a 5 kb genomic region on chromosome 3 with an IRES LacZ MC1 Neo cassette. The homologous arms consisted of a 3 kb 5' fragment and a 2.1 kb 3' fragment. Lex-1 129S5/SvEvBrd ES cells were transfected with the targeting construct and injected into C57BL/6 blastocysts to generate chimeras. Chimeras were bred to albino C57BL/6J-Tyr^{c-2j} mice (The Jackson Laboratory) to generate F1 progeny. F1 hybrids were crossed to generate initial Mendelian ratios (Table 1). Mice

Figure 1: Design of targeting constructs to inactivate PDGF-C. a) A linear diagram of the PDGF-C protein showing the CUB (orange) and GFD (green) above the exons that correspond to these protein domains. b) The targeting strategy for *Pdgfc*^{tm1lex} mice, which removes exons 4 and 5. c) The targeting strategy for the *Pdgfc*^{tm1Nagy} strain, which removes exon 2 Ding, et al. [5] Abbreviations : splice acceptor (SA), internal ribosomal entry site (IRES), complement components C1r/C1s sea urchin EGF bone morphogenic protein 1 (CUB), beta galactosidase neomycin fusion protein (β GEO), fusion polypeptide (A) tail (pA), Lac Z gene encoding beta galactosidase (Lac Z), enhancer, promoter, and neomycin phosphotransferase (MC1/ HSVtk and Neomycin).

were further backcrossed to a C57BL/6 background six times to generate the Mendelian ratio for C57BL/6 (Table 1). These mice can be obtained from the Mutant Mouse Regional Resource Centers (<http://www.mmrrc.org/index.php>) supported by the NIH. Hemizygous *Pdgfra* mice, *Pdgfra*^{tm11(egfp)sor}, were purchased from The Jackson Laboratory (stock # 007669). Animals were housed at the University of Washington, which is an Association

for the Assessment and Accreditation of Laboratory Animal Care approved facility, and all experiments were performed with the University of Washington Institutional Animal Care and Use Committee approval.

Necropsy and Histology

Homozygote *Pdgfc*^{tm1lex} mice (n = 4) and WT C57BL/6

Table 1: Heterozygous *Pdgfc*^{tm1lex} breeding pairs in two backgrounds produce offspring with normal Mendelian distribution.

Cohort	No. of animals	+/+	<i>Pdgfc</i> ^{tm1lex/+}	<i>Pdgfc</i> ^{tm1lex} / <i>Pdgfc</i> ^{tm1lex}	Chi sq value
129Sv/EvBrd					
observed	99	26	50	23	0.19
expected		25	50	25	
C57BL/6					
observed	265	55	147	63	3.7
male					
observed	146	29	83	34	3.1
expected		37	73	37	
female					
observed	119	26	64	29	0.83
expected		30	59	30	

Male and female heterozygous *Pdgfc*^{tm1lex/+} mice were bred and the genotypes of the resulting offspring were determined from DNA extracted from tail snips by PCR. Two different genetic backgrounds, 129SvBrd and C57BL/6, were analyzed. The expected number of pups with a specific genotype was calculated based on the total number of pups analyzed. Analysis of normal Mendelian distribution was determined by Chi square analysis with two degrees of freedom. A Chi square number greater than 5.99 is statistically significant.

littermates (n = 4) aged 5 and 8 weeks were euthanized by CO₂ asphyxiation followed by complete necropsy. Blood was collected for chemistry and complete blood counts performed by Phoenix Central Laboratories (Everett, WA). Tissues were collected for histological analysis with immersion fixation in 10% phosphate-buffered formalin, 4-6 µm sections were made and stained with hematoxylin and eosin. Tissues examined included: lungs, esophagus, trachea, liver, kidneys, heart and great vessels, adrenal glands, gallbladder, brown and white adipose tissue, exocrine and endocrine pancreas, spleen, thyroid, submandibular, parotid and sublingual salivary glands, mesenteric lymph nodes, mesentery, preputial or clitoral glands, skeletal muscle, bladder, male accessory sex glands, testes or ovaries, haired skin, large and small intestine, glandular and non-glandular stomach, uterus and cross section of the head (eyes, middle and internal ears, oral and nasal cavities, cerebrum, cerebellum, olfactory lobes, brain stem, pituitary, tongue and teeth). All tissues were examined by a board-certified Veterinary Pathologist (PMT) and given a morphological diagnosis where applicable. Skeletons were processed by eviscerating, removing the brain and as much muscle tissue and fat as possible, followed by immersion in 95% ethanol for at least 72 hours, placed in acetone overnight, and stained the next night at 37°C with a solution of 70% ethanol, 5% glacial acetic acid, 11.6 µM Alcian blue, and 14.6 µM Alizarin red. The following day the skeletons were washed in 95% ethanol and cleared in 2% KOH for 2 days and transferred to 1% KOH until fully cleared, with the solution refreshed every 2 to 3 days until soft tissues were cleared, at which point the skeletons were transferred to 100% glycerol.

Genotyping

Genomic DNA was extracted from mouse tails by incubation overnight at 55°C in 20 µg/ml Proteinase K (life technologies) in lysisbuffer (200mMNaCl, 1%W/VSDS, 10mMTris-HCl, 1mMEDTA pH 8.0). Phenol chloroform extraction was performed, followed by

ethanol precipitation and resuspension in Tris-HCl 10mM EDTA 1mM pH 7.4 (TE). Polymerase chain reaction was carried out with 0.5 U GemTaq (MGQuest), supplied 5x buffer, and dNTPs to a final concentration of 0.2mM with primers 5' CCTGGTCAAGCGCTGTGG 3'(200nM), 5' TCTGGATTCATCGACTGTGG 3'(200nM), 5' ACGGCTAACATGGAGCACG 3' (100 nM). All primers were designed using Oligo Calc [21]. Cycling conditions were 95°C for 3 min, and 35 cycles of 95°C for 20 sec, 60°C for 30 sec, and 72°C for 30 sec with a final extension at 72°C for 10 min.

Southern blotting

The targeting construct was verified using standard methods as described [22]. Briefly, genomic DNA was extracted as described above and purified DNA was restriction digested using EcoR1 HF (New England Biolabs) at 37°C overnight. 10µg of DNA from *Pdgfc*^{tm1lex} homozygous, heterozygous, and wild-Type (WT) mice was loaded onto a Tris-acetate-EDTA (TAE) gel. Following electrophoresis, the gel was denatured in 0.4M NaOH, 1.5 M NaCl for 10min followed by neutralization in Tris-HCl with 1.5M NaCl, pH 7.4. DNA was transferred to Hybond N+ (GE Healthcare) nylon membrane in 10x SSC and cross-linked in a Stratalinker 1800 (Stratagene). Exonic DNA including exon 6 and the 3' UTR was used as a probe, amplified by 5' CCTTTTAGGTCCTTCAGTTGAGACC 3' and 5' ATCTATGCAAACAGGTTGGAGAAATCC 3'. The probe was labeled with 50 µCi [α-³²P] dCTP using random decamers (DECAprime II, Ambion) to a specific activity >108 dpm/µg. The blot was prehybridized with Quickhyb (Stratagene) at 68°C for 30 min and then incubated with the denatured probe (106dpm/ml) at 68°C for 2 hr. Labeled membranes were then washed in 2x SSC with 0.1% SDS and 0.2x SSC with 0.1% SDS at 60°C for 30 min each. The sizes of the digested genomic DNA were confirmed by comparison with 32P- dCTP end-labeled λHin III DNA marker (Fermentas).

RT-PCR analysis

Tissues were collected and flash frozen immediately in liquid nitrogen. RNA was extracted with Trizol (Invitrogen) as per the manufacturer's instructions, and cDNA synthesized from 0.5 µgRNA. Primers (F1) 5' CTCACGTGTGCTGCTACGAAGG 3' and (R3) 5' CCCTGCGATTCTCTGCTGCC 3' were used with the following conditions; 95°C for 3 min, and 35 cycles of 95°C for 15 sec, 58°C for 15 sec, and 72°C for 30 sec with a final extension at 72°C for 10min.

Cloning

WT and *Pdgfc^{tm1lex}* cDNA was amplified with primers 5' GCCCTCGCCCCAGTCAGC 3' and 5' CTCACGTGTGCTGCTACGAAGG 3' to generate *Pdgfc* and *Pdgfc^{tm1lex}* sequences. WT cDNA was amplified with primers 5' ATGGTGGTGAATCTAAATCTCCTC 3' and 5' CTCACGTGTGCTGCTACGAAGG 3' to generate the GFD construct. Additionally, a sequence containing a Kozak sequence and the *Pdgfc* signal peptide for secretion was added to the 5' end of the GFD by Amplification (i.e., 5'GCAGAATTGCCACCATGCTCCTCCTCGGCCT-CCTCCTGCTGACATCTGCCCTGGCCGGC-CAAAGAACGGGGACTCGGGCTGAGTCC3').

The *Pdgfc*, *Pdgfc^{tm1lex}*, and *GFD* sequences were cloned separately into pEF1/myc-His B plasmids (Life Technologies), but retained the termination codons which prevent translation of the myc-His tag. The plasmids were linearized with Mlu I (New England Biolabs).

Transfection and production of conditioned media (CM)

Cells [HEK293](ATCC® CRL1573™) were maintained at 37°C 95% humidity with 5% CO₂. Transfections were performed using the calcium phosphate method as described [23], and the cells were subjected to 500 µg/ml G418 (Life Technologies) for two weeks to select for cells expressing the following constructs: empty vector (pEF1empty), *pEF1Pdgfc^{GFD}*, *pEF1Pdgfc^{mut}*, or *pEF1Pdgfc^{FL}* to produce untagged proteins, *Pdgfc^{GFD}*, *Pdgfc^{mut}* and *Pdgfc^{FL}* respectively. Confluent cultures were allowed to condition media for 24 hours, at which point media were collected and frozen at -80°C. Baby Hamster Kidney (BHK) cells, which do not express *Pdgfra* (BHK 570), and BHK cells transfected with *Pdgfra* (BHK Rα) were a kind gift from Dr. Daniel Bowen-Pope [24].

Immunoblot analysis

SDS-PAGE and immunoblotting were carried out as described [25]. For PDGF-C detection membranes were incubated with goat anti-mouse PDGF-C antibody (1:1000, AF1447 R&D Systems) followed by incubation with an anti-goat Horseradish Peroxidase (HRP) conjugated secondary antibody and detection performed with ECL (Pierce). For ERK and p-ERK detection, membranes were first incubated with anti-phospho p44/42 MAPK (1:1000, 9101 Cell Signaling Technology) followed by an anti-rabbit conjugated secondary antibody. Primary antibody; secondary antibody complexes were detected with ECL Plus (GE Healthcare) and imaged with a Storm 840 phosphor imager (GE Healthcare). Immunoblots were then stripped with 2% SDS, 62.5 mM Tris,

pH 6.8 with 7 µl beta-mercaptoethanol per ml. Blots were then reprobed with anti-ERK1/2 pAb 7884 followed by secondary and ECL as above. Densitometry analyzes were performed using Image J software (NIH) and is presented as the relative value of the phosphorylated protein normalized to the total levels of the same protein after re-probing.

Results

Homologous recombination targeting strategy

We examined a *Pdgfc* mutant mouse, *Pdgfc^{tm1lex}*, in which exons 4 and 5 of the GFD are deleted using the targeting strategy depicted in Figure 1b. Surprisingly, a viable mouse resulted from this approach; in contrast to the *Pdgfc* KO mice, which results in perinatal lethality (*Pdgfc^{tm1nag}*, Figure 1c). Figure 1 shows the protein domain structure of PDGF-C and compares the different targeting approaches used to generate the two mutant strains. *Pdgfc^{tm1lex}* mice were derived from a 129S5/SvEvBrd embryonic stem cell line (Lex1) targeted by homologous recombination to replace exons 4 and 5. This strategy should eliminate transcription of the entire GFD (Figure 1b). *Pdgfc^{tm1nag}* mice were derived from R1 embryonic stem cells targeted by homologous recombination to replace exon 2 of PDGFC with an SA-IRES-β-geo-pA cassette [5], preventing transcription downstream of β-geo, including the CUB and GFD.

Verification of recombination

To confirm that our selection cassette was targeted correctly, we performed Southern blotting on genomic DNA isolated from homozygous *Pdgfc^{tm1lex}*, heterozygous *Pdgfc^{tm1lex}*, and WT littermates. Digestion of genomic DNA with EcoRI should produce a 12.4 kb band including exons 4, 5, 6, and the 3' untranslated region (UTR) from WT DNA, and a 6.5 kb band including exon 6 and the 3' UTR in correctly targeted *Pdgfc^{tm1lex}* mice (Figure 2a). A ³²P labeled DNA probe with a complementary sequence to exon 6 and the 3' UTR of *Pdgfc* was used to detect these 12.4 and 6.5 kb bands by hybridization and bands of the expected size were detected for homozygous *Pdgfc^{tm1lex}*, heterozygous *Pdgfc^{tm1lex}*, and WT mice (Figure 2b).

Pdgfc^{tm1lex} transcription and translation

3.4 Given our Southern blotting results, we next verified production of the expected *Pdgfc^{tm1lex}* transcript, which should result from transcription of exons 1, 2, and 3 of *Pdgfc* (Figure 1c). Attempts to amplify a transcript containing exon 3 and the internal ribosomal entry site (IRES) (Figure 3a, primers F1 and R1) or *lacZ* (Figure 3a, F1 and R2) did not produce a product (data not shown), suggesting the targeting construct may have facilitated skipping the KO cassette. RT-PCR of *Pdgfc^{tm1lex}* cDNA using primers F1 and R3 (Figure 3a) generated a 296 bp band, consistent with a transcript in which exons 1, 2, 3 and 6 remain (Figure 3b). Sequencing this amplicon revealed that indeed the region corresponding to WT exons 4 and 5 was removed, but exon 6 was spliced in frame to the 3' end of exon 3 to create a truncated transcript (Figure 4). To detect the full-length coding region of

PDGFC, we designed primers to anneal to the 5' and 3' UTRs, and found that the *Pdgfc*^{tm1lex} transcript retains the endogenous 5' and 3' UTRs (Figure 3a, F2 and R4) and associated regulatory elements (data not shown).

The *Pdgfc*^{tm1lex} mutant transcript is expected to have an expression pattern similar to WT *Pdgfc*, given that the selection cassette did not alter the *Pdgfc*-c 5' and 3' regulatory elements. The translated protein product of *Pdgfc*^{tm1lex} is expected to contain the C-terminal 38 amino acids of the GFD and the entire CUB domain, resulting in a predicted molecular weight of 22.5 kDa. We found that HEK293 cells transfected with plasmids expressing the coding regions for full length *Pdgfc*-c (*Pdgfc*-c^{FL}), *Pdgfc*^{tm1lex} (*Pdgfc*-c^{mut}), or *Pdgfc*-c GFD (*Pdgfc*-c^{GFD}) secrete proteins of the predicted molecular weights into culture media, as determined by immunoblot analysis (Figure 3c). Thus *Pdgfc*-c^{FL}, *Pdgfc*-c^{mut} and *Pdgfc*-c^{GFD}, are all stable protein products.

Signal transduction in response to conditioned medium

To demonstrate that the CUB domain of *Pdgfc*-c could activate *Pdgfra*, we assessed ERK phosphorylation in BHK cells treated with various Conditioned Media (CM). Media were conditioned by HEK293 cells transfected with plasmids expressing *Pdgfc*-c CUB, *Pdgfc*-c GFD, or an empty vector control. When CM was added to BHK 570 cells, which have no *Pdgfra*, no phosphorylation of ERK was detected (data not shown). When conditioned medium α was added to BHK R α, which have been transfected with *Pdgfra*, phosphorylation of ERK was detected in a time-dependent manner, with maximal phosphorylation attained after five minutes of exposure (Figure 5a). Media conditioned by HEK293 cells transfected with an empty vector control interestingly did show ERK phosphorylation in BHK R α cells but not in BHK 570 cells, albeit to a lesser extent than the PDGF-C constructs, suggesting that

		exon 3	exon 4	
Pdgfc	473	TCCACTACAGTATTATCATGCCACAAGTCACAGAAACCAC	512	
Pdgfc ^{tm1Lex}	473	TCCACTACAGTATTATCATGCCA-----	495	
Pdgfc	513	GAGTCCTTCGGTGTGCCCCCTTCATCTTTGTCATTGGAC	552	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	553	CTGCTCAACAATGCTGTGACTGCCTTCAGTACCTTGGAAG	592	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	593	AGCTGATTTCGGTACCTAGAGCCAGATCGATGGCAGGTGGA	632	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	633	CTTGACAGCCTCTACAAGCCAACATGGCAGCTTTTGGGC	672	
Pdgfc ^{tm1Lex}	495	-----	495	
			exon 5	
Pdgfc	673	AAGGCTTTCCTGTATGGGAAAAAAGCAAAGTGGTGAATC	712	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	713	TGAATCTCCTCAAGGAAGAGGTAAACTCTACAGCTGCAC	752	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	753	ACCCCGGAACCTCTCAGTGTCCATACGGGAAGAGCTAAAG	792	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	793	AGGACAGATACCATATTCTGGCCAGGTGTCTCCTGGTCA	832	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	833	AGCGCTGTGGAGGAAATTGTGCCTGTTGTCTCCATAATTG	872	
Pdgfc ^{tm1Lex}	495	-----	495	
Pdgfc	873	CAATGAATGTCAGTGTGTCCACGTAAAGTTACAAAAAAG	912	
Pdgfc ^{tm1Lex}	495	-----	495	
		exon 6		
Pdgfc	913	TACCATGAGGTCCTTCAGTTGAGACCAAAAAGTGGAGTCA	952	
Pdgfc ^{tm1Lex}	495	-----GTCCTTCAGTTGAGACCAAAAAGTGGAGTCA	512	

Figure 4: Sequence of cDNA from the 296 bp *Pdgfc*^{tm1lex} band shown in 3b compared to the consensus mouse sequence for PDGFC, CCDS17425.1. Exon junctions are indicated above the consensus sequence.

transfection of HEK293 cells induces the release of a molecule that can signal through *Pdgfra*. When BHK α cells are exposed to increasing ratio of CM to fresh medium we see an increase in intensity of ERK phosphorylation just as increasing the amount of recombinant *Pdgfc* increases ERK phosphorylation (Figure 5b). CM from *Pdgfc* GFD and *Pdgfc* CUB domain transfected HEK 293 cells maintains some ability to induce ERK phosphorylation even at low CM ratio to fresh medium.

Anatomic characterization

Originally derived on a 129S5/SvEvBrd background, *Pdgfc^{tm1lex}* mice were backcrossed to a C57BL/6 background. Homozygous F1 C57BL/6 x 129S5/SvEvBrd *Pdgfc^{tm1lex}* progeny had a hunched appearance, and gross skeletal analyzes demonstrated spina bifida (Figure 5a and 5b), which was confirmed by histology (data not shown). All other organs were grossly normal. After six backcrosses, no overt anatomical differences were noted between homozygous *Pdgfc^{tm1lex}* mice and WT C57BL/6 littermates, i.e. the spina bifida phenotype was rescued. Comprehensive histological analyses (see methods) conducted on 5 and 8-week old *Pdgfc^{tm1lex}* homozygous mice were unremarkable or showed incidental lesions, such as dermatitis or mild multifocal extramedullary hematopoiesis in the liver, which are known to be associated

with the C57BL/6 background [26]. Brains of *Pdgfc^{tm1lex}* mice were examined histologically and did not differ from those of WT littermates; clinical chemistry and blood counts were also unremarkable (data not shown).

Genotype ratios

We observed normal Mendelian ratios in the offspring of heterozygote *Pdgfc^{tm1lex}* breeding pairs on two genetic backgrounds (Table 1). We did not observe premature death in *Pdgfc^{tm1lex}* mice up to 12 months of age and did not see sex-dependent differences in viability on the C57BL/6 background, as has been reported for *Pdgfc^{tm1nag}* mice [20]. Similar to Fredriksson L, et al. [6] we observed a statistically significant decrease in body mass in C57BL/6 *Pdgfc^{tm1lex}* mice at 3 and 7 months (a 17 to 24% decrease, data not shown). To determine whether *Pdgfra* necessary for normal development in *Pdgfc^{tm1lex}* mice, we intercrossed hemizygous *Pdgfra* mice with heterozygous *Pdgfc^{tm1lex}* mice. Progeny resulting from this cross did not include mice that were homozygous *Pdgfc^{tm1lex}*, hemizygous *Pdgfra* (Table 2). Neonatal mice homozygous for *Pdgfc^{tm1lex}* and hemizygous for *Pdgfra* were born but failed to thrive and 100% died prior to the age of weaning. This result is surprising, as hemizygous *Pdgfra* mice are phenotypically normal [1,27]; we thus conclude that

Figure 5: PDGF-C CUB domain stimulates modest ERK phosphorylation in BHK cells expressing PDGFR α . HEK293 cells were transfected with an empty vector (empty), the CUB domain of PDGF-C (CUB), or the growth factor domain of PDGF-C (GF) and the conditioned media (CM) was transferred to BHK cell lines expressing PDGFR α .

a) Time-dependent ERK phosphorylation by PDGF-C CUB, PDGF-C GF, or empty vector (E). Immunoblot phospho-ERK1/2 in BHK α cells transfected with *Pdgfra* after addition of CM. corresponding densitometry measurements are shown to the right.
b) Varying amounts of GF CM, CUB CM, and empty vector CM with non-CM stimulated ERK phosphorylation while DMEM (left lane) and DMEM conditioned from non-transfected HEK293 cells weakly phosphorylated ERK. Corresponding densitometry measurements are shown to the right.
Note: no phosphorylation of ERK was seen in the parental BHK cells under similar conditions (data not shown).

Table 2: Heterozygous *pdgfc^{tm1lex}* breeding pairs with one copy of *pdgfra* do not produce *pdgfc^{tm1lex}* homozygous and hemizygous *pdgfra* offspring.

Cohort	No. of animals	<i>Pdgfc</i> +/+ <i>Pdgfra</i> +/-	<i>Pdgfc</i> +/- <i>Pdgfra</i> +/-	<i>Pdgfc</i> -/- <i>Pdgfra</i> +/-	<i>Pdgfc</i> +/+ <i>Pdgfra</i> ++	<i>Pdgfc</i> +/- <i>Pdgfra</i> ++	<i>Pdgfc</i> -/- <i>Pdgfra</i> ++	Chi sq value
observed	127	14	27	0	20	50	16	30
expected		16	32	16	16	32	16	

Male and female heterozygous *Pdgfr^{tm1lex}* /+ mice, with a single copy of *Pdgfra*, were bred, and the genotypes of the resulting offspring were determined from DNA extracted from tail snips by PCR. The expected number of pups with a specific genotype was calculated based on the total number of pups analyzed. Analysis of normal Mendelian distribution was determined by Chi squared analysis with five degrees of freedom. A Chi square number greater than 11.07 is statistically significant. *Pdgfc*-/- represents *Pdgfc^{tm1lex}* /^{tm1lex} mice.

Figure 6: Anatomic characterization of *Pdgfc^{tm1lex}* mice.

a) 129Sv/EvBrd x C57BL/6 F1 wild type mice have normal thoracic and lumbar vertebrae.
b) Spina bifida in the thoracic and lumbar region (arrow) of *Pdgfc^{tm1lex}* homozygous mice.

Pdgfc^{tm1lex} viability requires two alleles of *Pdgfra*. Histological and gross anatomical analysis of these neonatal animals revealed severe spina bifida encompassing a region from vertebrae T11 to L1 (Figure 6 a-c). Microscopic analysis revealed demyelinated spinal cords with excessive blood infiltration. Like *Pdgfc^{tm1nagv}* mice, homozygous *Pdgfc^{tm1lex}*, hemizygous *Pdgfra* mice had palatoschisis. These genetic data indicate that PDGF-C^{mut} interacts with *Pdgfra* in some novel way, as *Pdgfc^{tm1nagv}* mice have reduced viability, while *Pdgfc^{tm1lex}* mice have lethality only in conjunction with hemizygous *Pdgfra*.

Discussion

PDGF signaling is essential for normal development. In this study we analyzed a new PDGF-C mutant mouse strain and demonstrate that the homologous recombination strategy in this mouse results in an alternatively spliced mutant form of *Pdgfc* that lacks over 60% of the RNA encoding the GFD, but expresses the entire portion of RNA encoding the CUB domain. This truncated transcript likely results from pre-mRNA splicing, which is a complicated event relying on proper sequence of both the 3' and 5' ends of exons, as well as the proper sequence of the exons themselves [28]. The targeting construct in *Pdgfc^{tm1lex}* used the endogenous 3' splice acceptor sequence of exon 4, but

the remainder of exon 4 was replaced with viral and bacterial sequences (IRES and Lac Z, respectively), which are incompatible with eukaryotic splicing machinery. The removal of the 3' end of exon 4 makes splicing at this particular sequence less likely, due to the inability of U1 to enhance splice site recognition [29]. The 14 bases remaining of the endogenous exon 4 sequence are likely insufficient to promote splicing, and thus lead to exon skipping in *Pdgfc^{tm1lex}* mice.

The presumed *Pdgfc* protein that is translated from *Pdgfc^{tm1lex}* should not have any GFD function, as paralogs of PDGF-C, PDGF-A and PDGF-B, require cysteines for dimerization and intramolecular and intermolecular folding [14,15]. We hypothesized that the *Pdgfc^{tm1lex}* protein product (*Pdgfc^{mut}*), lacking 6 of the 8 conserved cysteines, would have compromised or absent GFD signal transduction activity. *Pdgfc^{mut}* is also missing the paralogous loops, I and II of the GFD, which are necessary for receptor binding by the PDGF-C paralog, *Pdgfr-b* [16,18]. Loop I has also been shown to be critical for receptor activation by the PDGF paralogs Placental Growth Factor (PlGF) and Vascular Endothelial Growth Factor B (VEGFB), as well as the viral protein VEGFE_{NZ-7} [30,31]. Loop III remains in PDGF-C^{mut}, but is not expected to bind *Pdgfra* in the absence of loops I, II and the cysteine required to form loop III. Additionally, PDGF-

Figure 7: Developmental divergence between wild-type and homozygous *Pdgfc*^{tm1lex}; hemizygous *Pdgfra* mice.

- Live P0 pups. Homozygous *Pdgfc*^{tm1lex}; hemizygous *Pdgfra* mice have dark brown linear protrusions at the level of lumbar spine (white arrows).
- Formalin-fixed homozygous *Pdgfc*^{tm1lex}; hemizygous *Pdgfra* P0 pup with dorsal skin dissected away. Note the protruding and incompletely closed vertebral lamina (arrows) and dark meningocele.
- And d) Histologic sections through the level of the lumbar spine with kidneys (K) and vertebral body or disc (D) indicated for orientation.
- Homozygous *Pdgfc*^{tm1lex}; hemizygous PDGFR α pup represented in b) the spinal cord and meninges have extensive hemorrhages. The arrow indicates misaligned lamina and there are no dorsal vertebral processes, epaxial skeletal muscles, or abundant subcutaneous tissue covering the spinal cord (contrast to d).
- Normal thoracic anatomy with proper orientation of vertebral lamina (arrows) and complete enclosure of the spine. Note the skin was removed during dissection.
- e) and f) Histological sections of the thoracic spine with lungs (L) indicated for orientation. e) Homozygous *Pdgfc*^{tm1lex}; hemizygous PDGFR α pups have severe ascending hemorrhagic myelomalacia.
- Corresponding cross section of a wild type mouse. Note that the pulmonary hemorrhage and extravasated red blood cells in the meninges are secondary to euthanasia.
- g) and h) Cross section of the sinuses and hard palate at the level of the vomeronasal organ (T1).
- Palatoschisis (cleft palate) is present in the Homozygous *Pdgfc*^{tm1lex}; hemizygous PDGFR α mouse (arrowhead).
- Wild-type mouse.

C^{mut} lacks arginine 231, which has specifically been shown to be necessary for cleavage of the CUB domain, and this cleavage has been suggested to be critical for *Pdgfra* activation. [9,10]. All of these structural differences suggest that PDGF-C^{mut} would not interact with *Pdgfra* in the same manner as does PDGF-C. Our data suggest CUB-mediated activation of *Pdgfra* and raise the possibility that the CUB domain interacts with *Pdgfra* outside of the ligand binding pocket or perhaps interacts with the receptor in conjunction with other proteins to influence cell signaling.

CUB domains of proteins other than PDGF-C are involved in a diverse range of functions, including complement activation, developmental patterning, tissue repair, axon guidance and angiogenesis, fertilization, hemostasis, inflammation, neurotransmission, receptor-mediated endocytosis, and tumor suppression [32-34]. CUB domains have even been reported to be involved in cell signaling [35-37]. The human version of the PDGF-C CUB domain stimulates proliferation of human coronary artery smooth muscle cells [38]. Our results show that the PDGF-C CUB domain stimulates modest ERK phosphorylation in BHK cells that express *Pdgfra*, but not in the parental BHK 570 cells, which do not express the receptor. These results suggest that the CUB domain interacts with *Pdgfra* to transduce intracellular signaling events. This notion is supported by the observations that pups who are homozygous *Pdgfc^{tm1lex}*; hemizygous *Pdgfra* (Table 2) were not viable. The precise mechanisms involved with CUB domain-receptor interactions and subsequent signal transduction events are unknown. Relative to the PDGF-C GFD, however, the CUB domain seems to be less potent in activating the receptor. *In vivo*, it is possible that in the absence of the GFD, the CUB domain transduces sufficient *Pdgfra* activity to prevent perinatal lethality in homozygous *Pdgfc^{tm1lex}* mice.

Genetic background appears to have a profound effect on the PDGF signaling pathway in mice. For example, the Patch mutant mouse (*Ph*), in which a segment of chromosome 5 including *Pdgfra* is deleted, has a phenotype that varies with background, as C57BL/6 homozygous *Ph* mice die earlier in development than do *Ph* mice on a CBA, or BALB/C background [1]. Likewise, the severity of abnormalities in targeted *Pdgfra* null mice varies depending on background, with only DBA mice surviving until birth [1,39]. Though our observations may be due in part to strain differences, *Pdgfc^{tm1lex}* and *Pdgfc^{tm1nag}* mice appear to have different viabilities and phenotypes. *Pdgfc^{tm1nag}* mice have developmental abnormalities on a 129S1/Sv*129X/SvJ background, specifically a lethal palate formation defect [5]. These mice are viable on a C57BL/6 background but have brain abnormalities [19,20]. Conversely, *Pdgfc^{tm1lex}* mice are viable in two backgrounds, C57BL/6 x 129S5/SvEvBrd and C57BL/6 though two alleles of *Pdgfra* are necessary for their viability. Mice that are homozygous for *Pdgfc^{tm1lex}* and hemizygous for *Pdgfra* die within days of birth and have severe spina bifida. Our results suggest that the CUB domain of *Pdgfc* performs a function in *Pdgfra* signaling. Future experiments are needed to determine whether *Pdgfc^{tm1nag}* mice on C57BL/6 background require two *Pdgfra* alleles. The availability of *Pdgfc^{tm1lex}* mice will facilitate additional genetic screens, either alone or in conjunction with

Pdgfc^{tm1nag} mice or other mutants, to determine the biological functions of the PDGF-C CUB domain.

Acknowledgments

Grant support: NHLBI, Cardiovascular Pathology training grant (NIH-HL007312) and HHMI program in Molecular Medicine (BJH), Herbert Coe Foundation, American Surgical Association Foundation, and the American College of Surgeons (KJR), Drug Metabolism Transport and Pharmacogenetics Research Fund in the School of Pharmacy, University of Washington (EJK), NCI, mechanisms of PDGF-C induced HCC (NIH-CA127228) (JSC).

Declarations

All animal studies described in this manuscript were performed with University of Washington Institutional Animal Care and Use Committee approval. The University of Washington is an Association for the Assessment and Accreditation of Laboratory Animal Care approved facility.

Sources of Support

This work was supported by the NHLBI, Cardiovascular Pathology training grant (NIH-HL007312) and HHMI program in Molecular Medicine (BJH), Herbert Coe Foundation, American Surgical Association Foundation, Fred Hutchinson CRC New Investigator Award and the American College of Surgeons (KJR), Drug Metabolism Transport and Pharmacogenetics Research Fund in the School of Pharmacy, University of Washington (EJK), NCI, Mechanisms of PDGF-C induced HCC (NIH-CA127228) (JSC).

References

1. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. *Development*. 1997;124(14):2691-2700.
2. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. *Genes Dev*. 1994;8(16):1888-1896.
3. Boström H, Willetts K, Pekny M, et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. *Cell*. 1996;85(6):863-873.
4. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C, et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. *Genes Dev*. 1994;8(16):1875-1887.
5. Ding H, Wu X, Bostrom H, Kim I, Wong N, Tsoi B, et al. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. *Nature genetics*. 2004;36(10):1111-1116.
6. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. *Cytokine & Growth Factor rev*. 2004;15(4):197-204.
7. Tallquist MD, Soriano P. Cell autonomous requirement for PDGFR alpha in populations of cranial and cardiac neural crest cells. *Development* 2003;130(3):507-518.
8. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. *Nature*. 1986;320(6064):695-699.

9. Li X, Pontén A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. *Nat Cell Biol.* 2000;2(5):302-9.
10. Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. *J Biol Chem.* 2001;276(29):27406-27414.
11. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. *Nat Cell Biol.* 2001;3(5):512-516.
12. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, et al. PDGF-D, a new protease-activated growth factor. *Nat Cell Biol.* 2001;3(5):517-521.
13. Reigstad LJ, Sande HM, Fluge Ø, Bruland O, Muga A, Varhaug JE et al. Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure. *J Biol Chem.* 2003;278(19):17114-17120.
14. Sauer MK, Donoghue DJ. Identification of nonessential disulfide bonds and altered conformations in the v-sis protein, a homolog of the B chain of platelet-derived growth factor. *Mol Cell Biol.* 1988;8(3):1011-1018.
15. Kenney WC, Haniu M, Herman AC, Arakawa T, Costigan VJ, Lary J, et al. Formation of mitogenically active PDGF-B dimer does not require interchain disulfide bonds. *J Biol Chem.* 1994;269(16):12351-9.
16. Kreysing J, Ostman A, van de Poll M, et al. Identification of three amino acid residues in the B-chain of platelet-derived growth factor with different importance for binding to PDGF alpha- and beta-receptors. *FEBS Lett.* 1996;385(3):181-184.
17. Fenstermaker RA, Poptic E, Bonfield TL, Knauss TC, Corsillo L, Piskurich JF, et al. A cationic region of the platelet-derived growth factor (PDGF) A-chain (Arg159-Lys160-Lys161) is required for receptor binding and mitogenic activity of the PDGF-AA homodimer. *J Biol Chem.* 1993;268(14):10482-10489.
18. Andersson M, Ostman A, Kreysing J, Bäckström G, Van de Poll M, Heldin CH. Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. *Growth Factors* 1995;12(2):159-64.
19. Fredriksson L, Nilsson I, Su EJ, Andrae J, Ding H, Betsholtz C, et al. Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. *Am J Pathol.* 2012;180(3):1136-1144. doi: 10.1016/j.ajpath.2011.12.006.
20. Eitner F, Bücher E, van Roeyen C, Kunter U, Rong S, Seikrit C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. *J Am Soc Nephrol.* 2008;19(2):281-289. doi: 10.1681/ASN.2007030290.
21. Kibbe WA. OligoCalc: an online oligonucleotide properties calculator. *Nucleic Acids Res.* 2007;35(Web Server issue):W43-6.
22. Crouthamel MH, Kelly EJ, Ho RJ. Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers. *Transgenic Res.* 2012;21(1):113-130. doi: 10.1007/s11248-011-9512-z.
23. Sambrook J, Russell DW. Calcium-phosphate-mediated Transfection of Eukaryotic Cells with Plasmid DNAs. *CSH Protoc* 2006;2006(1). doi: 10.1101/pdb.prot3871.
24. Ferns GA, Sprugel KH, Seifert RA, Bowen-Pope DF, Kelly JD, Murray M, et al. Relative platelet-derived growth factor receptor subunit expression determines cell migration to different dimeric forms of PDGF. *Growth Factors.* 1990;3(4):315-3.
25. Campbell JS, Riehle KJ, Brooling JT, Bauer RL, Mitchell C, Fausto N. Proinflammatory cytokine production in liver regeneration is Myd88-dependent, but independent of Cd14, Tlr2, and Tlr4. *J Immunol.* 2006;176(4):2522-2528.
26. Sundberg JP, Taylor D, Lorch G, Miller J, Silva KA, Sundberg BA et al. Primary follicular dystrophy with scarring dermatitis in C57BL/6 mouse substrains resembles central centrifugal cicatricial alopecia in humans. *Vet Pathol.* 2011;48(2):513-524. doi: 10.1177/0300985810379431.
27. Hamilton TG, Klinghoffer RA, Corrin PD, Soriano P. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. *Mol Cell Biol.* 2003;23(11):4013-4025.
28. Reed R, Maniatis T. A role for exon sequences and splice-site proximity in splice-site selection. *Cell.* 1986;46(5):681-690.
29. Yue BG, Akusjarvi G. A downstream splicing enhancer is essential for in vitro pre-mRNA splicing. *FEBS Lett.* 1999;451(1):10-14.
30. Anisimov A, Leppänen VM, Tvorogov D, et al. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. *Sci Signal.* 2013;6(282):ra52 doi: 10.1126/scisignal.2003905.
31. Kiba A, Yabana N, Shibuya M. A set of loop-1 and -3 structures in the novel vascular endothelial growth factor (VEGF) family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling. *J Biol Chem* 2003;278(15):13453-13461.
32. Thielens NM, Bersch B, Hernandez JF, et al. Structure and functions of the interaction domains of C1r and C1s: keystones of the architecture of the C1 complex. *Immunopharmacology.* 1999;42(1-3):3-13.
33. Nakamura F, Goshima Y. Structural and functional relation of neuropilins. *Adv Exp Med Biol.* 2002;515:55-69
34. Mahoney DJ, Mikecz K, Ali T, et al. TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation. *J Biol Chem.* 2008;283(38):25952-25962. doi: M802138200 [pii] 10.1074/jbc.M802138200.
35. Lee HX, Mendes FA, Plouhinec JL, et al. Enzymatic regulation of pattern: BMP4 binds CUB domains of Tolloids and inhibits proteinase activity. *Genes Dev.* 2009;23(21):2551-2562. doi: 10.1101/gad.1839309.
36. Hollway GE, Maule J, Gautier P, et al. Scube2 mediates Hedgehog signalling in the zebrafish embryo. *Dev Biol.* 2006;294(1):104-118.
37. Wu YY, Peck K, Chang YL, et al. SCUBE3 is an endogenous TGF-β receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. *Oncogene.* 2011;30(34):3682-3693. doi: onc201185 [pii] 10.1038/onc.2011.85.
38. Dijkmans J, Xu J, Masure S, et al. Characterization of platelet-derived growth factor-C (PDGF-C): expression in normal and tumor cells, biological activity and chromosomal localization. *The international journal of biochemistry & cell biology.* 2002;34(4):414-26.
39. McKinnon RD, Waldron S, Kiel ME et al. PDGF alpha-receptor signal strength controls an RTK rheostat that integrates phosphoinositol 3'-kinase and phospholipase Cgamma pathways during oligodendrocyte maturation. *J Neurosci.* 2005;25(14):3499-3508.